<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Volume Spike Investor &#187; IDMI</title>
	<atom:link href="http://vsinvestor.com/tag/idmi/feed" rel="self" type="application/rss+xml" />
	<link>http://vsinvestor.com</link>
	<description>Investing in stocks based on short term spikes in volume</description>
	<lastBuildDate>Sat, 05 Nov 2011 14:20:15 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2</generator>
		<item>
		<title>Price/Volume Surge: IDM Pharma, Inc. (IDMI)</title>
		<link>http://vsinvestor.com/2008/11/pricevolume-surge-idm-pharma-inc-idmi.html</link>
		<comments>http://vsinvestor.com/2008/11/pricevolume-surge-idm-pharma-inc-idmi.html#comments</comments>
		<pubDate>Tue, 18 Nov 2008 15:30:22 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[General]]></category>
		<category><![CDATA[IDMI]]></category>

		<guid isPermaLink="false">http://www.vsinvestor.com/?p=393</guid>
		<description><![CDATA[IDM Pharma, Inc. (NASDAQ: IDMI) is seeing a volume and major price surge right at the open.  The company received recommendation for approval of Mifamurtide for the treatment of patients with non-metastatic, resectable osteosarcoma in Europe from the Committee for Medicinal Products for Human Use of the European Medicines Agency.  The agency has issued a [...]]]></description>
			<content:encoded><![CDATA[<p>IDM Pharma, Inc. (NASDAQ: IDMI) is seeing a volume and major price surge right at the open.  The company received recommendation for approval of Mifamurtide for the treatment of patients with non-metastatic, resectable osteosarcoma in Europe from the Committee for Medicinal Products for Human Use of the European Medicines Agency.  The agency has issued a positive opinion and is recommending grant of a centralized marketing authorization for mifamurtide.  This is known as MEPACT in Europe, for the treatment of patients with non-metastatic, resectable osteosarcoma. This recommendation will be adopted at the next meeting in December, and it looks like final European Commission approval expected within 60 to 90 days thereafter.</p>
<p>At 9;32 AM EST this stock is up over 50% at $2.39 on 43,000 shares.  Its daily average is only about 123,000 shares and this one was briefly up by more than 70% before the open.</p>
<p>Jon C. Ogg<br />
November 18, 2008</p>
]]></content:encoded>
			<wfw:commentRss>http://vsinvestor.com/2008/11/pricevolume-surge-idm-pharma-inc-idmi.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

